163 related articles for article (PubMed ID: 3395104)
1. Animal model for evaluating the convulsive liability of beta-lactam antibiotics.
Williams PD; Bennett DB; Comereski CR
Antimicrob Agents Chemother; 1988 May; 32(5):758-60. PubMed ID: 3395104
[TBL] [Abstract][Full Text] [Related]
2. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
Day IP; Goudie J; Nishiki K; Williams PD
Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
[TBL] [Abstract][Full Text] [Related]
3. Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
Jin C; Jung I; Ku HJ; Yook J; Kim DH; Kim M; Cho JH; Oh CH
Toxicology; 1999 Nov; 138(2):59-67. PubMed ID: 10576583
[TBL] [Abstract][Full Text] [Related]
4. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.
Birnbaum J; Kahan FM; Kropp H; MacDonald JS
Am J Med; 1985 Jun; 78(6A):3-21. PubMed ID: 3859213
[TBL] [Abstract][Full Text] [Related]
5. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
Horiuchi M; Kimura M; Tokumura M; Hasebe N; Arai T; Abe K
Toxicology; 2006 May; 222(1-2):114-24. PubMed ID: 16549226
[TBL] [Abstract][Full Text] [Related]
6. Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats.
Sack K; Herhahn J; Marre R; Schulz E
Infection; 1985; 13 Suppl 1():S156-60. PubMed ID: 3863794
[TBL] [Abstract][Full Text] [Related]
7. Imipenem/cilastatin: rationale for a fixed combination.
Norrby SR
Rev Infect Dis; 1985; 7 Suppl 3():S447-51. PubMed ID: 3863220
[TBL] [Abstract][Full Text] [Related]
8. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.
Calandra G; Lydick E; Carrigan J; Weiss L; Guess H
Am J Med; 1988 May; 84(5):911-8. PubMed ID: 3284342
[TBL] [Abstract][Full Text] [Related]
9. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
Pastel DA
Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin.
Calandra GB; Ricci FM; Wang C; Brown KR
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():125-31. PubMed ID: 6583195
[TBL] [Abstract][Full Text] [Related]
11. The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.
Drusano GL; Standiford HC; Bustamante CI; Forrest A; Rivera G; Tatem B; Schimpff SC
Eur J Clin Microbiol; 1984 Oct; 3(5):468-70. PubMed ID: 6594235
[TBL] [Abstract][Full Text] [Related]
12. Seizure-like activity associated with imipenem-cilastatin.
Tse CS; Hernandez Vera F; Desai DV
Drug Intell Clin Pharm; 1987; 21(7-8):659-60. PubMed ID: 3608817
[No Abstract] [Full Text] [Related]
13. [Bone concentrations of imipenem after a dose of imipenem/cilastatin].
Wittmann DH; Kuipers TH; Fock R; Höll M; Bauernfeind A
Infection; 1986; 14 Suppl 2():S130-7. PubMed ID: 3463540
[TBL] [Abstract][Full Text] [Related]
14. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
[TBL] [Abstract][Full Text] [Related]
15. Thienamycin: development of imipenen-cilastatin.
Kahan FM; Kropp H; Sundelof JG; Birnbaum J
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():1-35. PubMed ID: 6365872
[TBL] [Abstract][Full Text] [Related]
16. Imipenem/cilastatin: the first carbapenem antibiotic.
Lyon JA
Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics of imipenem-cilastatin in neonates.
Gruber WC; Rench MA; Garcia-Prats JA; Edwards MS; Baker CJ
Antimicrob Agents Chemother; 1985 Apr; 27(4):511-4. PubMed ID: 3859243
[TBL] [Abstract][Full Text] [Related]
18. [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda H; Kawamura Y
Jpn J Antibiot; 2002 Jun; 55(3):270-80. PubMed ID: 12199111
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose pharmacokinetics of imipenem-cilastatin.
Drusano GL; Standiford HC; Bustamante C; Forrest A; Rivera G; Leslie J; Tatem B; Delaportas D; MacGregor RR; Schimpff SC
Antimicrob Agents Chemother; 1984 Nov; 26(5):715-21. PubMed ID: 6595963
[TBL] [Abstract][Full Text] [Related]
20. The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
